[Treatment of cancer-related pain-From pharmacotherapy to invasive procedures].

Hannes Hofbauer, Stefan Wirz, Peter Steffen, Kristin Kieselbach, Jens Keßler
{"title":"[Treatment of cancer-related pain-From pharmacotherapy to invasive procedures].","authors":"Hannes Hofbauer, Stefan Wirz, Peter Steffen, Kristin Kieselbach, Jens Keßler","doi":"10.1007/s00101-024-01488-0","DOIUrl":null,"url":null,"abstract":"<p><p>Depending on the stage of the tumor up to 80% of the patients suffer from cancer-related pain but treatment is often inadequate. Multiple causes can trigger pain and these can be due to the tumor itself, its secondary consequences but also treatment related. A differentiated assessment and individually tailored treatment of cancer-related pain not only improve the quality of life but also reduce the risk of pain chronification. A differentiation between nociceptive pain and pain caused by hypersensitivity is a mandatory requirement for adequate pharmacotherapy. There is a risk of inadequate pain control, particularly with a lack of consideration and treatment of hypersensitivity, e.g., with anticonvulsants or analgesic antidepressants. Opioids are an integral part of drug treatment for cancer-related pain and especially for the treatment of breakthrough cancer pain. The risk of abuse should be considered. Other substance groups are suitable for special pain situations or in cases refractory to treatment. Nonpharmacological treatment options should also be considered, in particular by offering low-threshold access to psychotherapeutic or psycho-oncological options. Invasive procedures can be a useful supplement. These range from patient-controlled subcutaneous or intravenous infusion pump systems and intrathecal drug administration up to neurolytic and ablative procedures. Due to the invasiveness of these procedures, an interdisciplinary approach is recommended to confirm the indications.</p>","PeriodicalId":72805,"journal":{"name":"Die Anaesthesiologie","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Die Anaesthesiologie","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s00101-024-01488-0","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Depending on the stage of the tumor up to 80% of the patients suffer from cancer-related pain but treatment is often inadequate. Multiple causes can trigger pain and these can be due to the tumor itself, its secondary consequences but also treatment related. A differentiated assessment and individually tailored treatment of cancer-related pain not only improve the quality of life but also reduce the risk of pain chronification. A differentiation between nociceptive pain and pain caused by hypersensitivity is a mandatory requirement for adequate pharmacotherapy. There is a risk of inadequate pain control, particularly with a lack of consideration and treatment of hypersensitivity, e.g., with anticonvulsants or analgesic antidepressants. Opioids are an integral part of drug treatment for cancer-related pain and especially for the treatment of breakthrough cancer pain. The risk of abuse should be considered. Other substance groups are suitable for special pain situations or in cases refractory to treatment. Nonpharmacological treatment options should also be considered, in particular by offering low-threshold access to psychotherapeutic or psycho-oncological options. Invasive procedures can be a useful supplement. These range from patient-controlled subcutaneous or intravenous infusion pump systems and intrathecal drug administration up to neurolytic and ablative procedures. Due to the invasiveness of these procedures, an interdisciplinary approach is recommended to confirm the indications.

[癌症相关疼痛的治疗--从药物治疗到侵入性手术]。
根据肿瘤的分期,高达80%的患者患有与癌症相关的疼痛,但治疗往往不足。多种原因可以引发疼痛,这些可能是由于肿瘤本身,其次要后果,但也与治疗有关。对癌症相关疼痛进行差异化评估和个性化治疗,不仅可以提高生活质量,还可以降低疼痛慢性化的风险。区分伤害性疼痛和过敏引起的疼痛是适当药物治疗的强制性要求。存在疼痛控制不充分的风险,特别是缺乏对过敏的考虑和治疗,例如使用抗惊厥药或镇痛抗抑郁药。阿片类药物是癌症相关疼痛药物治疗的重要组成部分,尤其是突破性癌症疼痛的治疗。应该考虑到滥用的风险。其他物质组适用于特殊疼痛情况或难以治疗的情况。还应考虑非药物治疗方案,特别是通过提供低门槛的心理治疗或心理肿瘤治疗方案。侵入性手术是一种有用的补充。这些范围从患者控制的皮下或静脉输注泵系统和鞘内给药到神经溶解和消融手术。由于这些手术的侵入性,建议采用跨学科的方法来确认适应症。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信